MGI Pharma Inc - Strategic Analysis Review

Summary

MGI PHARMA, INC., (MGI) a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary pharmaceutical products in the areas of oncology and acute care. Currently, the company is commercializing Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen in the oncology and acute care segment across the US. The company was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, Inc. in 1990.

This report presents an in-depth strategic and operational analysis of MGI Pharma Inc. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis on the company.

Scope

-The company’s strengths and weaknesses and areas of development or decline are analyzed. Strategic and operational factors are considered.
-The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
-The report contains critical company information – business structure and operations, company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.

Reasons to buy

-A quick “one-stop-shop” to understand the company.
-Enhance business/sales activities by understanding customers’ businesses better.
-Get detailed information and strategic analysis on companies operating in your industry.
-Identify prospective partners and suppliers – with key data on their businesses and locations.
-Capitalize on competitors’ weaknesses and target the market opportunities available to them.
-Scout for potential acquisition targets, with detailed insight into the companies’ strategic and operational performance.